Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMFMW5C)

Drug Name
MVA-BN Breast Drug Info
Synonyms MVA-BN-pRo (TN)
Indication
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMFMW5C

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostate specific antigen (KLK3) TTS78AZ KLK3_HUMAN Antagonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Prostate specific antigen (KLK3) DTT KLK3 2.524 3.991 2.248 4.76
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Prostate
The Studied Disease Prostate cancer [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostate specific antigen (KLK3) DTT KLK3 2.01E-01 -0.04 -0.09
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00629057) A Safety Trial of MVA-BN-PRO in Men With Androgen-Insensitive Prostate Cancer. U.S. National Institutes of Health.
2 Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Cancer Res. 2011 Aug 1;71(15):5235-44.